XML 29 R54.htm IDEA: XBRL DOCUMENT v2.4.1.9
Goodwill and Other Intangible Assets (Product Rights and License by Therapeutic Category) (Details) (USD $)
In Millions, unless otherwise specified
Dec. 31, 2014
Dec. 31, 2013
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]    
Finite-lived intangible assets, net $ 1,598.2us-gaap_FiniteLivedIntangibleAssetsNet $ 1,678.8us-gaap_FiniteLivedIntangibleAssetsNet
Product rights and licenses    
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]    
Finite-lived intangible assets, net 1,489.2us-gaap_FiniteLivedIntangibleAssetsNet
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_LicensingAgreementsMember
1,541.4us-gaap_FiniteLivedIntangibleAssetsNet
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_LicensingAgreementsMember
Therapeutic class disclosure threshold 5.00%myl_TherapeuticClassReportingThreshold
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_LicensingAgreementsMember
5.00%myl_TherapeuticClassReportingThreshold
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_LicensingAgreementsMember
Product rights and licenses | Allergy    
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]    
Finite-lived intangible assets, net 82.5us-gaap_FiniteLivedIntangibleAssetsNet
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_LicensingAgreementsMember
/ us-gaap_ProductOrServiceAxis
= myl_AllergyMember
95.9us-gaap_FiniteLivedIntangibleAssetsNet
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_LicensingAgreementsMember
/ us-gaap_ProductOrServiceAxis
= myl_AllergyMember
Product rights and licenses | Anti-infectives    
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]    
Finite-lived intangible assets, net 152.8us-gaap_FiniteLivedIntangibleAssetsNet
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_LicensingAgreementsMember
/ us-gaap_ProductOrServiceAxis
= myl_AntiInfectiveAgentsMember
194.2us-gaap_FiniteLivedIntangibleAssetsNet
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_LicensingAgreementsMember
/ us-gaap_ProductOrServiceAxis
= myl_AntiInfectiveAgentsMember
Product rights and licenses | Antineoplastic    
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]    
Finite-lived intangible assets, net 123.7us-gaap_FiniteLivedIntangibleAssetsNet
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_LicensingAgreementsMember
/ us-gaap_ProductOrServiceAxis
= myl_AntineoplasticMember
147.4us-gaap_FiniteLivedIntangibleAssetsNet
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_LicensingAgreementsMember
/ us-gaap_ProductOrServiceAxis
= myl_AntineoplasticMember
Product rights and licenses | Cardiovascular    
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]    
Finite-lived intangible assets, net 175.0us-gaap_FiniteLivedIntangibleAssetsNet
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_LicensingAgreementsMember
/ us-gaap_ProductOrServiceAxis
= myl_CardiovascularMember
235.8us-gaap_FiniteLivedIntangibleAssetsNet
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_LicensingAgreementsMember
/ us-gaap_ProductOrServiceAxis
= myl_CardiovascularMember
Product rights and licenses | Central Nervous System    
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]    
Finite-lived intangible assets, net 199.5us-gaap_FiniteLivedIntangibleAssetsNet
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_LicensingAgreementsMember
/ us-gaap_ProductOrServiceAxis
= myl_CentralNervousSystemMember
211.2us-gaap_FiniteLivedIntangibleAssetsNet
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_LicensingAgreementsMember
/ us-gaap_ProductOrServiceAxis
= myl_CentralNervousSystemMember
Product rights and licenses | Dermatological    
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]    
Finite-lived intangible assets, net 65.9us-gaap_FiniteLivedIntangibleAssetsNet
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_LicensingAgreementsMember
/ us-gaap_ProductOrServiceAxis
= myl_DermatologicalMember
79.6us-gaap_FiniteLivedIntangibleAssetsNet
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_LicensingAgreementsMember
/ us-gaap_ProductOrServiceAxis
= myl_DermatologicalMember
Product rights and licenses | Endocrine and Metabolic    
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]    
Finite-lived intangible assets, net 54.8us-gaap_FiniteLivedIntangibleAssetsNet
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_LicensingAgreementsMember
/ us-gaap_ProductOrServiceAxis
= myl_EndocrineAndMetabolicMember
72.4us-gaap_FiniteLivedIntangibleAssetsNet
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_LicensingAgreementsMember
/ us-gaap_ProductOrServiceAxis
= myl_EndocrineAndMetabolicMember
Product rights and licenses | Gastrointestinal    
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]    
Finite-lived intangible assets, net 67.6us-gaap_FiniteLivedIntangibleAssetsNet
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_LicensingAgreementsMember
/ us-gaap_ProductOrServiceAxis
= myl_GastrointestinalMember
95.2us-gaap_FiniteLivedIntangibleAssetsNet
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_LicensingAgreementsMember
/ us-gaap_ProductOrServiceAxis
= myl_GastrointestinalMember
Product rights and licenses | Hematological Agents    
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]    
Finite-lived intangible assets, net 294.5us-gaap_FiniteLivedIntangibleAssetsNet
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_LicensingAgreementsMember
/ us-gaap_ProductOrServiceAxis
= myl_HematologicalAgentsMember
14.9us-gaap_FiniteLivedIntangibleAssetsNet
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_LicensingAgreementsMember
/ us-gaap_ProductOrServiceAxis
= myl_HematologicalAgentsMember
Product rights and licenses | Respiratory System    
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]    
Finite-lived intangible assets, net 78.3us-gaap_FiniteLivedIntangibleAssetsNet
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_LicensingAgreementsMember
/ us-gaap_ProductOrServiceAxis
= myl_RespiratoryAgentsMember
147.4us-gaap_FiniteLivedIntangibleAssetsNet
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_LicensingAgreementsMember
/ us-gaap_ProductOrServiceAxis
= myl_RespiratoryAgentsMember
Product rights and licenses | Other    
Schedule of Product Rights and Licenses by Therapeutic Class [Line Items]    
Finite-lived intangible assets, net $ 194.6us-gaap_FiniteLivedIntangibleAssetsNet
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_LicensingAgreementsMember
/ us-gaap_ProductOrServiceAxis
= myl_OtherProductsMember
[1] $ 247.4us-gaap_FiniteLivedIntangibleAssetsNet
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_LicensingAgreementsMember
/ us-gaap_ProductOrServiceAxis
= myl_OtherProductsMember
[1]
[1] Other consists of numerous therapeutic classes, none of which individually exceeds 5% of total product rights and licenses.